Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 228

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration

Open access
Lee, Jay M., Lee, Mi-Heon, Garon, Edward, Goldman, Jonathan W., Salehi-Rad, Ramin, Baratelli, Felicita E., Schaue, Dörthe, Wang, Gerald, Rosen, Fran, Yanagawa, Jane, Walser, Tonya C., Lin, Ying, Park, Stacy J., Adams, Sharon, Marincola, Francesco M., Tumeh, Paul C., Abtin, Fereidoun, Suh, Robert, Reckamp, Karen L., Lee, Gina, Wallace, William D., Lee, Sarah, Zeng, Gang, Elashoff, David A., Sharma, Sherven, Dubinett, Steven M. · 2017 · Clinical Cancer Research

Abstract

Purpose: A phase I study was conducted to determine safety, clinical efficacy, and antitumor immune responses in patients with advanced non–small cell lung carcinoma (NSCLC) following intratumoral administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expressing the CCL21 gene (Ad-CCL21-DC). We evaluated safety and tumor antigen–specific immune responses following in situ vaccination (ClinicalTrials.gov: NCT01574222). Experimental Design: Sixteen stage IIIB/IV NSCLC subjects received two vaccinations (1 × 106, 5 × 106, 1 × 107, or 3 × 107 DCs/injection) by CT- or bronchoscopic-guided intratumoral injections (days 0 and 7). Immune responses were assessed by tumor antigen–specific peripheral blood lymphocyte induction of IFNγ in ELISPOT assays. Tumor biopsies were evaluated for CD8+ T cells by IHC and for PD-L1 expression by IHC and real-time PCR (RT-PCR). Results: Twenty-five percent (4/16) of patients had stable disease at day 56. Median survival was 3.9 months. ELISPOT assays revealed 6 of 16 patients had systemic responses against tumor-associated antigens (TAA). Tumor CD8+ T-cell infiltration was induced in 54% of subjects (7/13; 3.4-fold average increase in the number of CD8+ T cells per mm2). Patients with increased CD8+ T cells following vaccination showed significantly increased PD-L1 mRNA expression. Conclusions: Intratumoral vaccination with Ad-CCL21-DC resulted in (i) induction of systemic tumor antigen–specific immune responses; (ii) enhanced tumor CD8+ T-cell infiltration; and (iii) increased tumor PD-L1 expression. Future studies will evaluate the role of combination therapies with PD-1/PD-L1 checkpoint inhibition combined with DC-CCL21 in situ vaccination. Clin Cancer Res; 23(16); 4556–68. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2821

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 228

Metadata

Authors
Lee, J. M., Lee, M.-H., Garon, E., Goldman, J. W., Salehi-Rad, R., Baratelli, F. E., Schaue, D., Wang, G., Rosen, F., Yanagawa, J., Walser, T. C., Lin, Y., Park, S. J., Adams, S., Marincola, F. M., Tumeh, P. C., Abtin, F., Suh, R., Reckamp, K. L., Lee, G., Wallace, W. D., Lee, S., Zeng, G., Elashoff, D. A., Sharma, S., & Dubinett, S. M.
Venue
Clinical Cancer Research
Published
2017-08-14
Volume
23
Issue
16
Pages
4556-4568
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2611460276
Cited by
228
References
5
FWCI
5.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2821
The paper
Lee, J. M., Lee, M.-H., Garon, E., Goldman, J. W., Salehi-Rad, R., Baratelli, F. E., Schaue, D., Wang, G., Rosen, F., Yanagawa, J., Walser, T. C., Lin, Y., Park, S. J., Adams, S., Marincola, F. M., Tumeh, P. C., Abtin, F., Suh, R., Reckamp, K. L., . . . Dubinett, S. M. (2017). Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2821

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.